Conduit Pharmaceuticals Inc.
13F holders, Q1 2024 (March 31)18holders
$3.67avg. 13F price*
At the end of Q1 2024, 18 institutions reported holding Conduit Pharmaceuticals Inc. in their 13F filings. The largest holders were Barclays PLC ($3.0M), Vanguard Group Inc. ($763K) and BlackRock Inc. ($630K).
- Company
- Conduit Pharmaceuticals Inc.
- CUSIP
- 20678X106
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $800K |
| Exits | 1 | $75K |
Ownership 18 holders
| Barclays PLC | 0.00% | No change | 804,292 | $3.0M |
| Vanguard Group Inc. | 0.00% | Reduce -12.0% | 207,892 | $763K |
| BlackRock Inc. | 0.00% | Add +24.4% | 171,582 | $630K |
| Geode Capital Management, LLC | 0.00% | Reduce -0.5% | 138,937 | $510K |
| Goldman Sachs Group Inc. | 0.00% | New | 68,550 | $252K |
| Marshall Wace, LLP | 0.00% | New | 61,954 | $227K |
| Qube Research & Technologies Ltd | 0.00% | New | 40,985 | $150K |
| JPMorgan Chase & Co. | 0.00% | Add +318.4% | 26,830 | $98K |
| Northern Trust Corp. | 0.00% | Add +2.9% | 21,786 | $80K |
| Y-Intercept (Hong Kong) Ltd | 0.01% | New | 19,272 | $71K |
| State Street Corp. | 0.00% | New | 15,300 | $56K |
| Morgan Stanley | 0.00% | New | 11,787 | $43K |
| Bank of Montreal | 0.00% | No change | 10,000 | $38K |
| Bank of America Corp. | 0.00% | Add +1336.8% | 8,003 | $29K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +82.6% | 3,862 | $14K |
| Wells Fargo & Company | 0.00% | Add +4.2% | 75 | $275 |
| UBS Group AG | 0.00% | New | 41 | $151 |
| Macquarie Group Ltd. | 0.00% | New | 195 | $1 |
"% of holder's portfolio" is CONDUIT PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Conduit Pharmaceuticals Inc. the manager owns.